Clinical Trial Update: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ONC-392 in combination with pembrolizumab for platinum-resistant ovarian cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Carcinoma
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ONC-392
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: OncoC4, Inc. | Conditions: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Status: ACTIVE_NOT_RECRUITING